Brevan Howard Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Brevan Howard Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46,138	Closed	-$126K	–	2202
2026 Q1	$126K	Sell	46,138 -122,892	-73%	-$389K	﹤0.01%	1986
2025 Q4	$625K	Sell	169,030 -94,246	-36%	-$305K	0.01%	989
2025 Q3	$698K	Buy	263,276 +184,561	+234%	+$357K	﹤0.01%	1104
2025 Q2	$77.1K	Buy	78,715 +45,782	+139%	+$45.8K	﹤0.01%	1797
2025 Q1	$47.4K	Buy	+32,933	New	+$60.7K	﹤0.01%	1091
2024 Q2	–	Sell	-69,025	Closed	-$185K	–	1146
2024 Q1	$185K	Buy	+69,025	New	+$168K	﹤0.01%	815

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Brevan Howard Capital Management's ESPR Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 46,138 shares — an estimated $126K sold.

Brevan Howard Capital Management first reported a position in ESPR in Q1 2024 and held it in 6 quarters. The position peaked at $698K in Q3 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Brevan Howard Capital Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 46,138 Esperion Therapeutics shares in Q2 2026, an estimated $126K.
Brevan Howard Capital Management first reported a position in Esperion Therapeutics in Q1 2024 and held it in 6 quarters.
Brevan Howard Capital Management's Esperion Therapeutics position peaked at $698K in Q3 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.